Contact | Print version | PDF version | Send article | RSS feed

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

21 Aug 2007 - Cangene Corporation reported that its contract with the U.S. Centers for Disease Control and Prevention for the supply of Vaccinia Immune Globulin Intravenous (Human) ("VIG") has been extended for five more years. The original five-year contract was signed in August 2002, and under that contract Cangene developed and delivered VIG product to the U.S. Strategic National Stockpile ("SNS"). Although a supply of product is already maintained within the SNS, the extended contract supports licensing requirements, ongoing stability studies, further clinical testing and development projects, and could provide for future orders.
 
VIG is a hyperimmune product to be used in treating and preventing certain types of severe complications that may be associated with smallpox vaccination, and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified, specialty antibodies made from plasma.